Illumina reports Q1 adjusted EPS $1.15, consensus $1.05

Reports Q1 revenue $1.09B, consensus $1.07B. “Illumina (ILMN) delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy,” said Jacob Thaysen, Chief Executive Officer of Illumina. “Demand for NovaSeq X is increasing as we help our clinical customers expand into new application areas. With our strong first quarter performance, we are raising our full-year revenue and EPS guidance.”